Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype

Molecular Medicine

Volumn 8, Issue 11, 2002, Pages 750-760

  Abraham, W T ^a   Gilbert, E M ^c   Lowes, B D ^a   Minobe, W A ^a   Larrabee, P ^b   Roden, R L ^a   Dutcher, D ^a   Sederberg, J ^a   Lindenfeld, J A ^a   Wolfel, E E ^a   Shakar, S F ^a   Ferguson, D ^a   Volkman, K ^b   Linseman, J V ^a   Quaife, R A ^a   Robertson, A D ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; CARVEDILOL; METOPROLOL; MYOSIN HEAVY CHAIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CARDIOMYOPATHY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HEART CONTRACTION; HEART DILATATION; HEART EJECTION FRACTION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE BIOPSY; HEART VENTRICULOGRAPHY; HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SARCOPLASMIC RETICULUM;

EID: 0242585474     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402039     Document Type: Article

References (42)

1. Feldman AM, Ray PA, Silan CM, Mercer JA, Minobe W, Bristow MR. (1991) Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation 83: 1866-1872.
2. Bristow MR. (1998) Why does the myocardium fail? New insights from basic science. Lancet 352(suppl I): 8-14.
3. 1-adrenergic receptors in the failing human heart. Circulation 87: 454-463.
4. 1 receptor messenger RNA abundance in the failing human heart. J. Clin. Invest. 92: 2737-2745.
5. Mercadier JJ, Lompre AM, Duc P, et al. (1990) Altered sarcoplasmic reticulum Ca-ATPase gene expression in the human ventricle during end-stage heart failure. J. Clin. Invest. 85: 305-309.
6. Nakao K, Minobe WA, Roden RL, Bristow MR, Leinwand LA. (1997) Myosin heavy chain gene expression in human heart failure. J. Clin. Invest. 100: 2362-2370.
7. Lowes BD, Minobe WA, Abraham WT, et al. (1997) Changes in gene expression in the intact human heart: down-regulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J. Clin. Invest. 100: 2315-2324.
8. Lowes BD, Gilbert EM, Abraham WT, et al. (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346: 1357-1365.
9. Lopau K, Mark J, Schramm L, Heidbreder E, Wanner C. (2000) Hormonal changes in brain death and immune activation in the donor. Transplant. Int. 13: S282-S285.
10. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. (1989) Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483-490.
11. Gilbert EM, Abraham WT, Olsen S, et al. (1996) Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817-2825.
12. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. (1992) Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc. Natl. Acad. Sci. U.S.A. 89: 5251-5255.
13. Adolph EA, Subramanian A, Cserjesi P, Olson EN, Robbins J. (1993) Role of myocyte-specific enhancer-binding factor (Mef-2) in transcriptional regulation of the α-cardiac myosin heavy chain gene. J. Biol. Chem. 268: 5349-5352.
14. Wang AM, Doyle MV, Mark DF. (1989) Quantitation of mRNA by the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A. 86: 9717-9721.
15. Engelhardt S, Bohm M, Erdmann E, Lohse MJ. (1996) Analysis of beta-receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J. Am. Coll. Cardiol. 27: 146-154.
16. Eichhorn EJ, Bristow MR. (1996) Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 94: 2285-2296.
17. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. (1995) Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J. Am. Coll. Cardiol. 5: 1154-1161.
18. Quaife RA, Gilbert EM, Christian PE, et al. (1996) Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 78: 779-784.
19. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. (1996) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol. 29: 1060-1066.
20. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. (1998) Effects of carvedilol on right ventricular function in chronic heart failure. Am. J. Cardiol. 81: 247-250.
21. Lowes BD, Gill WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. (1999) Effects of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am. J. Cardiol. 83: 1201-1205.
22. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. (1993) Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 87(suppl VI): VI-17-VI-23.
23. Cetta F, Michels VV. (1995) The natural history and spectrum of idiopathic dilated cardiomyopathy, including HIV and peripartum cardiomyopathy. Curr. Opin. Cardiol. 10: 332-338.
24. Zaret BL, Wackers FJ. (1991) Measurement of right ventricular function. In Gerson MC, ed. Cardiac Nuclear Medicine, 2nd ed. New York: McGraw-Hill.
25. Bristow MR, Mestroni L, Bohlmeyer T, Gilbert EM. (2001) Dilated cardiomyopathies. In Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's the Heart, Volume 2, 10th ed. New York: McGraw-Hill; pp. 1947-1966.
26. Swynghedauw B. (1986) Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol. Rev. 66: 710-771.
27. Nadal-Ginard B, Mahdavi V. (1989) Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J. Clin. Invest. 4: 1693-1700.
28. Schwartz K, Chassagne C, Boheler KR. (1993) The molecular biology of heart failure. J. Am. Coll. Cardiol. 22: 30A-33A.
29. Colucci WS. (1997) Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. 80: 15L-25L.
30. Bristow MR, Anderson FL, Port JD, et al. (1991) Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 1024-1039.
31. Rahko PS. (1994) Comparative efficacy of three indexes of left ventricular performance derived from pressure-volume loops in heart failure induced by tachypacing. J. Am. Coll. Cardiol. 23: 209-218.
32. Cohn JN, Ferrari R, Sharpe N, on behalf of the International Forum on Cardiac Remodeling. (2000) Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J. Am. Coll. Cardiol. 35: 569-582.
33. Weiss A, Leinwand LA. (1996) The mammalian myosin heavy chain gene family. Ann. Rev. Cell. Dev. Biol. 12: 417-439.
34. Miyata S, Minobe WA, Bristow MR, Leinwand LA. (2000) Myosin heavy chain isoform expression in the failing and non-failing human heart. Circ. Res. 86: 386-390.
35. Vanburen P, Harris DE, Alpert NR, Warshaw DM. (1995) Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ. Res. 77: 439-444.
36. Imamura SI, Matsuoka R, Hiratsuka E, et al. (1991) Adaptational changes of MyHC gene expression and isoenzyme transition in cardiac overloading. Am. J. Physiol. 260: H73-H79.
37. Herron TJ, McDonald KS. (2002) Small amounts of α-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ. Res. 90: 1-4.
38. Litten RZ 3rd, Martin BJ, Low RB, Alpert NR. (1982) Altered myosin isozyme patterns from pressure-overloaded and thyrotoxic hypertrophied rabbit hearts. Circ. Res. 50: 856-864.
39. Reiser PJ, Portman MA, Ning XH, Schomisch Moravee C. (2001) Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am. J. Physiol. 280: H1814-H1820.
40. Razumova MV, de Tombe PP, Moss RL. (2001) Simulations predict that expression of small amounts of αMHC in mammalian ventricle significantly accelerates the rate of rise of force. Biophys. J. 80: 261a.
41. Jones WK, Grupp IL, Doetschman T, et al. (1996) Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J. Clin. Invest. 98: 1906-1917.
42. Morkin E. (2000) Control of myosin heavy chain gene expression. Microsc. Res Tech. 50: 522-531.